Merz Pharmaceuticals GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merz Pharmaceuticals GmbH
The diabetic retinopathy candidate failed on its Phase II primary endpoint, but showed efficacy on a key secondary endpoint that the company hopes to use as the Phase III primary outcome measure.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
- Other Names / Subsidiaries
- BioteCon Therapeutics GmbH
- Cabochon Aesthetics, Inc.
- ON Light Sciences, Inc.
- Ulthera, Inc.
- Merz Pharmaceuticals GmbH
- Merz Pharma France
- Merz North America, Inc.
- Merz Pharma (Schweiz) Ag
- Merz Pharma GmbH
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.